secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2025-12-30T23:59:59+00:00
Accession:  0001213900-25-126358
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics completes commercial-scale IL-6 antibody production for Symphony cartridges
--------------------------------------------------------------------------------

- Completed commercial-scale production of polyclonal and monoclonal anti-IL-6 antibodies meeting internal performance criteria.
- Antibodies intended for Symphony cartridge manufacturing for clinical and potential future commercial applications.
- Sufficient material to support production of over 9 million Symphony cartridges; additional capacity established.
- Symphony System remains under development, subject to further validation and FDA clearance before marketing.
- Monoclonal antibodies designated as detection antibodies showed acceptable binding, specificity, and signal performance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390025126358/0001213900-25-126358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390025126358/ea0271231-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-126358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer